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1. Introduction 
The natural product perophoramidine (1) and its dehalogenated 
derivative 2 were first reported by Ireland in 2002.1 These 
compounds are structurally related to another family of alkaloids 
known as the communesins (for example 3F, Figure 1).2 Since 
their isolation, 1-3 have proved an inspiration to synthetic chemists 
resulting in numerous total syntheses and a wide range of elegant 
approaches.3-5  
 
Figure 1: Structures of the natural products (1-3F) relevant to this work.  
 
These natural products all possess an indolo[2,3-b]quinoline 
core structure but it is the vicinal all-carbon quaternary centers that 
present the major synthetic challenge. Early work on the synthesis 
of dehaloperophoramidine (2) by Rainier4a involved alkylation of 
lactam 4 to give 5 under basic conditions via enolate 6 (Scheme 
1a). This reaction occurred to give a single diastereomer with 
addition of allyl iodide occurring from the opposite side to the 
CH2CH2NR2 group on C-10b. In addition, Weinreb has reported 
the conversion of 7 to 8 via enolate 9.5c In Weinreb’s example it 
was argued that the bulky BOM protected primary alcohol at C-
12a controlled C11- alkylation of 9 leading to the allyl group being 
 
Scheme 1: a) The previously reported alkylation methods by Rainier4a and Weinreb5c; 
Reagents and conditions:a) KOtBu, allyl iodide, THF, 0 oC 89%, b) KOtBu, allyl iodide, 
THF, -78 oC – rt, 87%. b) Two proposed methods for installing the required all-carbon 
quaternary stereocenters from our ketone 14. 
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directed onto the same face as the existing CH2CH2NR2 group at 
C-10b. These results suggest that the stereochemical outcome of 
alkylation at C11, in the absence of a C12a-substituent, is highly 
likely to lead to the new substituent being place on the opposite 
face to the CH2CH2NR2 group at C-10b. We therefore considered 
an approach towards both ester 10 (in a plan to prepare 
dehaloperophoramidine (2)) and ester 11 (for the communesins) 
via a common intermediate 12 (Scheme 1b). Ester 12 could be 
constructed from alcohol 13 which could itself be formed from 
ketone 14.6 Here we describe the outcome of this plan and discuss 
a series of interesting issues that arose during these studies. 
2. Results and Discussion 
We have previously reported the synthesis of ketone 14 (Scheme 
1b).6 In this new work, preliminary investigations involved 
nucleophilic addition to 14 to assess the stereochemical outcome 
(Scheme 2). Reduction of 14 with NaBH4 led to alcohol 15 in high 
yield (89%) as a single diastereoisomer. The relative 
stereochemistry of 15 was confirmed by X-ray crystallographic 
analysis and indicated hydride attack on 14 had occurred on the 
opposite face to the allyl group at C-10b, as expected. 
Furthermore, treatment of the N-benzylated analogue 16 led to the 
formation of 17 (95%) as a single diastereoisomer. The relative 
stereochemistry of 17 was proposed to be the same as 15 (see Table 
S1 for 1H NMR comparison of 15 and 17 and further discussion). 
 
 
 
 
 
 
 
 
 
Scheme 2: Diastereoselective reductions of ketones 14 and 16. In each case the 
nucleophile approached from the opposite face to the allyl group at C-10b. The structure 
of 15 was confirmed by X-ray crystallographic analysis and this was used to infer the 
relative stereochemistry in 17. 
This result encouraged us to continue our approach to installing 
the all-carbon quaternary stereocenters in 1 and 2 using the C10b 
stereocenter as the control unit. In brief, as this section of our 
approach has been previously described in a communication 
format,4d 14 was converted to 18 using MeLiBr in the presence of 
chloroiodomethane (Scheme 3). With 18 in hand, attempts were 
made to perform an acid-catalysed rearrangement of the epoxide. 
The addition of 5 equivalents of BF3⸱OEt2 to 18 led to a complex 
mixture of products. However, treatment of the crude sample with 
NaBH4 and subsequent recrystallisation from CDCl3/ hexane 
afforded alcohol 19. The relative configuration of 19 was assigned 
using X-ray crystallographic analysis. Alternatively, reductive 
opening of 18 with 2.5 equivalents of BF3⸱OEt2 in the presence 
of NaBH3CN gave alcohol 13 in an unoptimised 35% yield after 
recrystallisation from methanol. X-ray crystallographic analysis 
confirmed the structure of 13 and demonstrated that it was the C-
11 epimer of alcohol 19. Analogous reaction conditions were 
applied to ketone 20 (Scheme 3). The change in the N-R1 
protecting group from methyl to benzyl was required to enable a 
late stage deprotection to give the required unprotected amidine.4d 
The change from the allyl to the crotyl side chain was part of one 
potential solution to the challenge of developing an asymmetric 
approach to 2.6 Ketone 20 was converted to 21 in an optimized 
90% yield and underwent successful reductive epoxide opening to 
alcohol 22. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Scheme 3: Formation of alcohols 19, 13 and 22. The structures of these compounds were 
confirmed by X-ray crystallographic analysis. Reaction conditions: a MeLi-LiBr, ClCH2I, 
THF, -78 oC, 0.5 h, rt, 12 h; b BF3⸱OEt2, THF, -78 oC, 3 h; c NaBH4, MeOH, rt, 2 h; d 
BF3OEt2, NaBH3CN, -78 oC -rt, 18 h. 
 
     Again, X-ray crystallographic analysis of 22 confirmed the 
relative stereochemistry of the new C-11 stereocenter. 
      With alcohols 13 and 22 in hand, attempts were made to install 
the required all-carbon quaternary stereocenters at C10b and C11. 
Alcohol 13 underwent Jones oxidation to carboxylic acid 23, 
followed by methylation to give ester 12 in 52% yield (2 steps, 
Scheme 4). Loss of product likely occurred during the work up 
stage as the zwitterionic nature of 23 probably renders it soluble in 
the aqueous phase. Encouragingly, alkylation of 12 with allyl 
bromide under basic conditions afforded the desired ester 10 as a 
single diastereoisomer in 59% yield. X-ray crystallographic 
analysis of 10 confirmed that alkylation had been directed to the 
opposite face of the existing C-10b CH2CH2NR2 group, as 
expected. Therefore 10 was viewed as a potentially suitable 
intermediate en route to dehaloperophoramidine (2).  
Scheme 4: Formation of all-carbon quaternary stereocenters with the desired relative 
stereochemistry in dehaloperophoramidine and the communesins. Reagents and 
conditions: a CrO3, H2SO4, H2O, Me2CO, rt; b Me3SiCHN2, MeOH, rt; c LiHMDS, allyl 
bromide, THF, -78 °C to rt, 16 h, 59%; d LDA, H2CO, THF, -78 °C to rt, 1.5 h, 76%. 
 
Ester 12 was also considered as a possible intermediate towards 
members of the communesin family of natural products. 
Alkylation of 12 with formaldehyde in the presence of LDA 
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afforded 11 in good yield (76%) as a single diastereoisomer. X-
ray crystallographic analysis confirmed the structure of 11 and 
showed that it possessed 1-carbon units at different oxidation 
levels that afforded 11 in good yield (76%) as a single 
diastereoisomer. X-ray crystallographic analysis confirmed the 
structure of 11 and showed that it possessed 1-carbon units at 
different oxidation levels that were either syn-(CO2Me) or anti-
(CH2OH) to the allyl group at C-10b. Selective functionalisation 
of the ester would be required to generate the necessary syn-2-
carbon unit required in the communesins. 
 
     However, when the analogous reactions were carried out on the 
crotyl-containing alcohol 22, Jones oxidation of carboxylic acid 
24, followed by methylation to ester 25 could only be achieved in 
an overall yield of 25%. The low yield rendered this approach 
unsuitable for the planned approach to 2. Unfortunately, the yield 
could not be improved despite an extensive screen of reaction 
conditions and oxidising agents (Table S2). Further analysis of the 
Jones oxidation reaction of 22 by LCMS and LRMS indicated 
significant accumulation of a degradation product during the 
reaction (m/z = 352.96). After isolation via semi-preparative 
HPLC, this compound was tentatively assigned as achiral 26 
(Scheme 4). 1H NMR analysis of 26 indicated loss of the crotyl 
group. Furthermore, the diastereotopic benzyl CH2 protons present 
in 22 (two doublets) now appeared as a singlet in 26 (see SI for a 
further discussion and one proposed mechanism for this reaction). 
As the presence of the crotyl group in 22 appeared to have a 
detrimental effect on the yield of 23, it was decided to modify this 
group by oxidative cleavage (Scheme 5). This transformation 
would be required at some stage in any synthesis of 2 to remove 
the one excess carbon atom. 
   
     Dihydroxylation followed by oxidative cleavage of the alkene 
in 20, followed by in-situ reduction of the intermediate aldehyde 
afforded 27 in high yield (88%). Alcohol 27 was initially O-
benzylated before undergoing epoxide formation to give 28 in an 
analogous manner to the synthesis of 18 and 21 (Scheme 3). 
Disappointingly, the conversion of 28 to alcohol 29 in the presence 
of BF3⸱OEt2 could not be achieved and a complex mixture of 
unassignable products was isolated. This was likely due to initial 
Lewis-acid mediated O-benzyl deprotection prior to degradation 
of the starting material. To overcome this issue, TBDPS protected 
epoxide 30 was synthesized. Gratifyingly, 30 underwent the 
desired reductive epoxide opening to give 31 in a 55% yield. Due 
to its acid labile silyl protecting group (TBDPS), 31 was deemed 
unsuitable for oxidation under the highly acidic Jones conditions. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Scheme 5: Synthesis of 31 and unexpected air oxidation of intermediate 32 to 33. Reagents 
and conditions: a OsO4, NMO, THF:H2O (9:1), 18 h, rt. b PhI(OAc)2, DCM, 2h, rt then 
NaBH(OAc)3, EtOAc, 2 h, rt, 88% (2 steps). c i) Benzyl TCA, TMSOTf, DCM, 0 oC – rt, 
4 h; c ii) TPDBS-Cl, imidazole, DCM, rt, 1 h. d ClICH2, MeLi:LiBr, THF, 6 h, -78 oC – 
rt, 51% for 28 (2 steps); 71% for 30 (2 steps). e BF3.Et2O, NaBH3CN, THF, - 78oC – rt, 
16 h, 55%. f DMP, CDCl3, rt, 48 h, 65%.  
 
Instead, Dess-Martin periodinane (DMP) was chosen in an attempt 
to form aldehyde 32. Interestingly, whilst 32 was the initial 
product formed upon the addition of 1.2 equivalents of DMP to 31 
(full consumption of the starting material was observed after 0.5 
hours, Figure SI1) it was found that α-hydroxylation occurred at 
C-11 to form 33 after extended reaction times (48 h, Figure SI1. 
See Figure SI2 for further discussion of the oxidation and 
assignment of the stereochemistry in 33). Furthermore, α-
hydroxylation was still found to occur even after isolation and 
rapid purification by column chromatography of aldehyde 32. This 
indicated 32 was air sensitive and that molecular oxygen was the 
likely source of the undesired oxidation. Air oxidation at benzylic 
positions α- to an aldehyde has been reported previously in the 
total synthesis of Fredericamycin A by Boger and co-workers.7 
 
Whilst the transformation of 31 to 33 was intriguing, it prevented 
further progress towards the desired natural products 1-3. Having 
struggled to develop a reproducible and scalable method for the 
construction of the all-carbon quaternary stereocenters via the 
above methods, a new approach was investigated. Reassessment 
of the structure of key intermediate 12 (Scheme 1b) showed that 
whilst the presence of the ester moiety adjacent to C-11 ultimately 
permitted alkylation to give 10 and was at the correct oxidation 
level for this atom in 2, significant further development of the ester 
would be required to incorporate the necessary nitrogen atoms. It 
was therefore proposed that the installation of a cyano group at C-
11 could achieve the analogous acidification of the C-11 proton to 
facilitate alkylation and that it may be possible to incorporate the 
cyano nitrogen into advanced intermediates (Scheme 6a). After 
initial attempts to convert the alcohol in 17 to a cyano group (via 
a C-11 bromide) proved unsuccessful, it was decided to try and 
incorporate the cyano group using tosylmethyl isocyanide 
(TosMIC). An initial attempt to convert the ketone in 14 to the 
cyano group with TosMIC failed to yield the desired nitrile 34 
(Scheme 6b). Instead, the achiral 35, in which the allyl group had 
migrated from C-10b to C-11, was isolated in 61% yield (see SI 
for further discussion on the structural assignment of 35 and two 
possible mechanisms).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Scheme 6: A) Synthesis of achiral 35. Reagents and conditions: a TosMIC, DME  t-
BuOK, 0 °C to rt, 1.5 h; B) Synthesis of allyl-nitrile 38 and proposed di-cyclisation of 
target intermediate 39. Reagents and conditions: b OsO4, NMO, THF, H2O, rt, 24 h, PPTS; 
c Me2C(OMe)2, CH2Cl2, rt, 48 h, 70% (2 steps); d TosMIC, t-BuOK, t-BuOH, DME, 0 °C 
to rt, 1 h; e LiHMDS, allyl bromide, THF, - 78 °C to rt, 34% (2 steps). 
 
      As the presence of the allyl side chain at C-10b again appeared 
to be providing an alternative reaction pathway, it was decided to 
functionalise this group prior to attempting the TosMIC-mediated 
reductive cyanation (Scheme 6c). Dihydroxylation of ketone 14, 
followed by protection of the resulting diol via acetal formation 
with 2,2-dimethoxypropane led to formation of 36 and its C10’’ 
epimer.  Careful chromatographic purification of the resulting the 
diastereomeric mixture 36a/b, gave a highly enriched sample of 
36a (20:1). The relative stereochemistry at C10’’ in 36a could not 
be assigned. Reductive cyanation of 36a gave 37a/b as a mixture 
of C-11 epimers in ratio of 3:1 with only trace signals 
corresponding to the C10’’ epimers being observed in the 1H NMR 
spectrum. 
 
Finally, allylation of the diastereomeric mixture of 37a/b was 
achieved by treatment with allyl bromide in the presence of 
LiHMDS to give 38 (34%, 2 steps) as essentially a single isomer 
after purification. Although 38 was obtained as a single 
diastereoisomer, it was not possible to obtain X-ray 
crystallographic data to assign the relative stereochemistry (the 
structure currently assigned to 38 is tentative and is based on the 
assumption that alkylation was directed by the CH2CH-acetal 
group on C-10b in the absence of a C12-substituent (see Scheme 
1)). 
     Having successfully synthesized allyl-nitrile 38, future work 
will focus on the synthesis of intermediate 39 (Scheme 6a) via 
functionalization of the C-3 units at C-10b and C-11 and de-
methylation of the amidine moiety. It is hoped that 39 could be a 
direct precursor to 2 upon undergoing a double cyclisation to 
construct the second required amidine. 
 
3. Conclusions 
      In conclusion, we have described the construction of all-carbon 
quaternary stereocenters within intermediates aimed at both 
dehaloperophoramidine (2) and the communesins. The reactions 
involved have included highly diastereoselective base mediated 
alkylation at the C-11 position of ester 12 with both allyl bromide 
and formaldehyde. In addition, a 2-steps protocol for the 
construction of all-carbon quaternary stereocenters via TosMIC 
addition to 36 and alkylation is described. Further investigations 
into the synthesis of the target natural products via these 
intermediates will be reported in due course. 
4. Experimental 
General methods 
 
All chemicals and solvents were purchased from Sigma Aldrich 
(UK) or Alfa-Aesar and used without further purification.  All 
reactions were carried out under a positive pressure of nitrogen or 
argon in flame or oven-dried glassware. Thin layer 
chromatography (TLC) analysis was performed on silica pre-
coated SIL G-25 UV254 sheets (layer: 0.25 mm silica gel with 
fluorescent indicator UV254, Alugram, UK).  Compounds were 
visualized by UV light (UV lamp, model UVGL-58, Mineralight 
LAMP, Multiband UV-254/365 nm) and stained with potassium 
permanganate.  Flash column chromatography was carried out on 
silica gel (40-63 μm, Fluorochem, UK). Melting points were 
measured with an Electrothermal 9100 capillary melting point 
apparatus and are uncorrected. Fourier Transform infra-red spectra 
(FT-IR) were acquired on a Perkin Elmer paragon 1000 FT 
spectrometer.  Absorption maxima are reported in wavenumbers 
(cm -1). Unless otherwise stated, 1H and 13C NMR spectra were 
measured at room temperature (298 K) on a Bruker DPX 400 
(1H = 400 MHz, 13C = 100 MHz); Bruker Avance 300 
(1H = 300 MHz, 13C = 75 MHz) and a Bruker Avance 500 
(1H = 500.1 MHz, 13C = 125 MHz).  Deuterated solvents were 
used and 1H NMR chemical shifts were internally referenced to 
CHCl3 (7.26 ppm) in chloroform-d1 solution. Chemical shifts are 
expressed as δ in unit of ppm and coupling constants are recorded 
in Hz. Data processing was carried out using TOPSPIN 2 NMR 
version (Bruker UK, Ltd) or MestreNova 9.0 program (Bruker UK 
Ltd). In 1H NMR assignment the multiplicity used is indicated by 
the following abbreviations:  s = singlet, d = doublet, dd = doublet 
of doublets, t = triplet, q = quartet, m = multiplet, brs = broad 
singlet.  Signals of protons and carbons were assigned, as far as 
possible, by using the following two-dimensional NMR 
spectroscopy techniques:  [1H-1H] COSY, [1H-13C] HSQC 
(Heteronuclear Single Quantum Coherence) and long range [1H-
13C] HMBC (Heteronuclear Multiple Bond Connectivity). Mass 
spectrometry analysis (electrospray mode, ES; chemical ionization 
mode, CI) were performed by Ms Caroline Hosburgh and were 
recorded on a high performance orthogonal acceleration reflecting 
TOF mass spectrometer operating in positive and negative mode, 
coupled to a Waters 2975 HPLC. 
 
 
Experimental procedures 
 
(±)-10b-allyl-5-methyl-5,11-dihydro-10bH-indolo[2,3-
b]quinoline-11-ol (15) 
 
NaBH4 (164 mg, 4.34 mmol) was added to a solution of 14 (250 
mg, 0.867 mmol) and MeOH (10 mL).  After 2 hours, water (2 
mL) was added and the MeOH was evaporated at reduced 
pressure.  The aqueous residue was extracted with CH2Cl2 (3 x 5 
mL).  The combined extracts were dried (MgSO4) and the CH2Cl2 
was concentrated in vacuo.  The residue was purified by flash 
chromatography (10% to 20% EtOAc/hexane) the afford the title 
compound 15 as a colourless crystalline solid (224 mg, 0.771 
mmol, 89%).  Crystals suitable for X-ray analysis were obtained 
from EtOH.  Mp 181-182 oC; IR (KBr) νmax: 3416, 3076, 1557 cm-
1; HRMS (CI) m/z calcd for C19H19N2O 291.1497, found 291.1496; 
1H NMR (300 MHz, CDCl3)  7.60 (ddd, J = 7.5, 1.5, 1.0 Hz, 1H), 
7.47 (d, J = 7.5 Hz, 1H), 7.38-7.24 (m, 3H), 7.13 (td, J = 7.5, 1.0 
Hz, 1H), 7.05-6.99 (m, 2H), 5.26-5.12 (m, 1H), 4.98 (d, J = 7.5 
Hz, 1H), 4.78-4.71 (m, 2H), 3.57 (s, 3H), 2.94 (d, J = 7.5 Hz, 1H), 
2.63 (dd, J = 13.5, 7.0 Hz, 1H), 2.32 (dd, J = 13.5, 7.5 Hz, 1H); 
13C NMR (75 MHz, CDCl3)  173.1, 155.8, 140.1, 137.2, 132.7, 
128.94, 128.87, 126.7, 125.8, 123.1, 123.0, 122.6, 118.5, 117.5, 
114.3, 72.1, 57.0, 33.6, 32.9. 
 
(±)-10b-allyl-5-benzyl-10b,11-dihydro-5H-indolo[2,3-
b]quinolin-11-ol (17) 
 
NaBH4 (164 mg, 4.34 mmol) was added to a solution of 16 (100 
mg, 0.275 mmol) and MeOH (5 mL).  After 2 hours, water (5 mL) 
was added and the mixture was diluted with DCM (10 mL).  The 
organic layer was washed with brine; dried (MgSO4) then 
concentrated in vacuo.  The residue was purified by flash 
chromatography (10% to 20% EtOAc/hexane) the afford the title 
compound 17 as a colourless crystalline solid (91 mg, 0.249 mmol, 
91%). IR (ATR) νmax: 3293, 1631, 1553 cm-1; HRMS (ESI) m/z 
calcd. for C25H23N2O 367.1810, found 367.1813; 
1H NMR (500 
MHz,CDCl3) δ 7.59 (dt, J = 7.5, 1.5 Hz, 1H), 7.50 (dd, J = 7.0, 1.0 
Hz, 1H), 7.36 – 7.27 (m, 6H), 7.26 – 7.17 (m, 2H), 7.08 (dtd, J = 
13.5, 7.5, 1.0 Hz, 2H), 6.92 (dd, J = 8.0, 1.0 Hz, 1H), 5.77 (d, J = 
16.5 Hz, 1H), 5.31 – 5.20 (m, 1H), 5.04 (d, J = 7.0 Hz, 1H), 4.94 
(d, J = 16.5 Hz, 1H), 4.87 – 4.80 (m, 2H), 2.77 (dd, J = 14.0, 7.0 
Hz, 1H), 2.67 (d, J = 7.0 Hz, 1H), 2.44 (dd, J = 14.0, 7.5 Hz, 1H); 
13C NMR (126 MHz, CDCl3) δ 173.1, 155.9, 139.6, 137.4, 136.9, 
132.8, 128.8, 127.4, 126.7, 126.6, 125.6, 123.3, 123.1, 122.7, 
118.7, 117.8, 115.2, 72.1, 57.0, 49.8, 33.4. 
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(±)-10b-allyl-11-hydroxymethyl-5-methyl-5,11-dihydro-10bH-
indolo[2,5-b]quinoline (19) 
 
An impure sample of SI1 (7 mg) was dissolved in MeOH (0.5 mL) 
and NaBH4 (5 mg, 0.132 mmol) was added.  After 2 h, water (0.5 
mL) was added and the mixture was extracted with CH2Cl2 (3 x 1 
mL).  The combined extracts were dried (MgSO4) and the solvent 
was evaporated at reduced pressure to give the title compound 19 
as a colourless solid (7 mg).  A crystal suitable for X-ray analysis 
was obtained from CDCl3/hexane. IR (film) νmax: 3192, 1556, 
1493, 1469, 1455, 1403, 1219, 1132, 1063, 922, 753, 737 cm-1; 
HRMS (CI) m/z calcd for C20H20N2O 304.1576, found 304.1577; 
1H NMR (300 MHz, CDCl3)  7.36-7.21 (m, 5H), 7.08-6.99 (m, 
3H), 5.52-5.38 (m, 1H), 4.98-4.94 (m, 1H), 4.81-4.74 (m, 1H), 
3.61 (s, 3H), 3.51 (dd, J = 14.0, 8.5 Hz, 1H), 3.39-3.31 (m, 2H), 
2.47 (dd, J = 13.5, 8.0 Hz, 1H), 2.25 (dd, J = 13.5, 7.0 Hz, 1H).  
 
(±)-10b-allyl-11-hydroxymethyl-5-methyl-5,11-dihydro-10bH-
indolo[2,5-b]quinoline (13)  
  
A stirred mixture of 18 (560 mg, 1.84 mmol) and NaBH3CN (291 
mg, 4.63 mmol) in THF (20 mL), maintained under an argon 
atmosphere, was cooled to -10 °C.  A solution of BF3.OEt2 (0.51 
mL, 4.06 mmol) in THF (5 mL) was added over a period of 20 
min.  After 2 hours, an additional portion of BF3.OEt2 (0.12 mL, 
0.955 mmol) in THF (1 mL) was added and stirring was continued 
for 1 hour at -10 °C.  NaHCO3(aq) (50 mL) was added and the 
reaction mixture was allowed to warm to room temperature.  The 
aqueous solution was extracted with CH2Cl2 (4 x 30 mL), the 
combined extracts were washed with brine (50 mL), dried 
(MgSO4), and the CH2Cl2 was evaporated at reduced pressure.  
The residue was crystallised from MeOH/water to afford the title 
compound 13 as a colourless crystalline solid (196 mg, 0.644 
mmol, 35%).  Crystals from MeOH were suitable for X-ray 
analysis.  Mp 190-191 oC; Anal. calcd for C20H20N2O: C, 78.92; H, 
6.62; N, 9.20. Found: C, 78.99; H, 6.66; N, 9.53; IR (KBr) νmax: 
3201, 2928, 2876, 1616, 1557, 1495, 1472, 1456, 1401, 1316, 
1222, 1139, 1105, 1051, 986, 931, 809, 758, 652, 499 cm-1; HRMS 
(CI) m/z calcd for C20H20N2O 304.1576, found 304.1569; 
1H NMR 
(300 MHz, CDCl3)  7.68 (ddd, J = 8.0, 1.5, 1.0 Hz, 1H), 7.26-
7.23 (m, 4H), 7.14-6.98 (m, 3H), 5.10-4.96 (m, 1H), 4.73-4.62 (m, 
3H), 4.48-4.39 (m, 1H), 3.58 (s, 3H), 3.12-3.07 (m, 1H) 2.38-2.35 
(m, 2H), 2.01 (dd, J = 7.5, 3.5, 1H); 13C NMR (75 MHz, CDCl3)  
173.9, 156.0, 141.4, 136.7, 132.6, 128.8, 128.2, 127.4, 125.4, 
123.7, 123.2, 122.3, 118.2, 117.4, 114.6, 61.7, 54.3, 44.2, 35.0, 
33.1. 
 
(±)-5,10b-dihydro-10b-crotyl-5-benzyl-10bH-indolo[2,3-
b]quinolin-11-one (20) 
 
A solution of alkoxide was prepared by the careful addition of 
sodium (1.72 g, 75 mmol, 2 eq.) to 3-buten-2-ol (21.0 g, 
243 mmol, 3.2 eq.) in THF (5 mL).  This solution was added to a 
stirring solution of SI2 (10 g, 37.5 mmol, 1 eq.; the synthesis of 
SI2 has been reported previously4d) in THF (200 mL).  The 
resulting reaction mixture was stirred at room temperature for 
18 h.  Saturated aqueous NH4Cl was then added (100 mL) and the 
solvent removed at reduced pressure.  The resulting residue was 
suspended in water (100 mL) and extracted with DCM 
(3 × 100 mL).  The combined organic extracts were dried 
(MgSO4) and the solvent removed at reduced pressure. The crude 
material was dissolved in THF (150 mL) and stirred at reflux for 
5 h.  After cooling to room temperature, the residue was purified 
by column chromatography (Hexane/EtOAc, 95:5 to 90:10) to 
afford the desired product 20 as a yellow microcrystalline powder 
(8.50 g, 22.5 mmol, 60%).  Mp 148-150 °C; IR (KBr) νmax cm-1  
1697, 1558, 1469; HRMS (ES+) m/z calcd for C23H20O4Na 
401.1630, found 401.1614;  1H NMR δH (300 MHz, CDCl3) 7.95 
(dd, J = 7.5, 1.5 Hz, 1H), 7.70 (dd, J = 7.5 Hz, 0.5 Hz, 1H), 7.53-
7.21 (m, 8H), 7.20-6.97 (m, 3H), 5.92 (d, J = 16.5 Hz, 1H), 5.35-
5.19 (m, 1H), 5.11-4.96 (m, 2H), 2.87 (dd, J = 13.5 Hz, 6.5 Hz, 
1H), 2.46 (dd, J = 13.5 Hz, J = 8.0 Hz, 1H), 1.53 (dd, J = 6.0 Hz, 
J = 0.5 Hz, 3H); 13C NMR δC (100 MHz, CDCl3) 192.9, 172.3, 
153.5, 144.8, 136.9, 133.6, 131.6, 129.0, 128.7, 128.4, 127.8, 
127.6, 126.7 (2C), 124.8, 123.1, 122.6, 122.5, 119.3, 118.7, 115.5, 
66.5, 49.6, 44.3, 17.9.  
 
(±)-10b-crotyl-5-benzyl-5,11-dihydro-10bH-indolo[2,5-
b]quinolin-11-spiro-2'-oxirane (21)   
 
To a mixture of 20 (4.90 g, 12.9 mmol, 1 eq.) in THF (50 mL) at -
78 °C was added slowly MeLi-LiBr (12.2 mL of a 1.5 M solution, 
19.4 mmol, 1.5 eq) over a period of 20 minutes.  
Chloroiodomethane (1.22 mL, 19.4 mmol, 1.5 eq.) was added and 
the reaction mixture stirred for 30 min at -78 °C before allowing 
to warm to room temperature.  After stirring for 18 h at room 
temperature, saturated aqueous NH4Cl solution (50 mL) was 
added and the solvent removed at reduced pressure.  Water 
(50 mL) and Et2O (50 ml) were added, the organic phase was 
separated and the aqueous phase further extracted with Et2O 
(3 x 50 mL).  The combined organic extracts were dried (MgSO4) 
and filtered through a plug of silica.  The resulting organic solution 
was left to slowly evaporate at ambient temperature until nearly 
dry (ca. 10 mL of Et2O remaining).  The desired product 21 was 
obtained as large colourless crystals (4.45 g, 11.35 mmol, 88%).   
Mp 138-141 °C; IR (KBr) νmax 3029, 2938, 1813, 1689, 1558, 1491 
cm-1; HRMS m/z (ES+) calcd for C27H25N2O  393.1967, found 
393.1956;  1H NMR δH (400 MHz, CDCl3) 7.43-7.16 (m, 10H), 
7.07-6.97 (m, 2H), 6.91 (dd, J = 8.0 Hz, 0.5 Hz, 1H), 5.91 (d, 
J = 16.5 Hz, 1H), 5.33-5.21 (m, 1H), 4.97-4.83 (m, 2H), 3.07 (d, 
J = 5.5 Hz, 1H), 2.81 (dd, J = 14.0, 6.0 Hz, 1H), 2.62 (dd, J = 14.0, 
8.5 Hz 1H), 2.53 (d, J = 5.5 Hz, 1H), 1.45 (d, J = 6.0 Hz, 3H); 13C 
NMR δC (100 MHz, CDCl3) 172.6, 155.5, 141.5, 137.0, 134.6, 
129.7, 129.4, 128.9, 128.8, 127.4, 126.6, 124.2, 123.8, 123.5, 
123.3, 122.8, 122.8, 118.0, 115.1, 60.2, 55.3, 53.6, 49.9, 37.3, 
17.9.  
(±)-10b-crotyl-11-hydroxymethyl-5-benzyl-5,11-dihydro-10bH-
indolo[2,5-b]quinoline (22)  
 
To a stirring solution of 21 (5.30 g, 13.5 mmol, 1 eq.) in THF 
(150 mL) at -78 °C was added NaBH3CN (2.12 g, 33.7 mmol, 
2.5 eq.).  A solution of BF3.OEt2 (6.78 mL, 54.0 mmol, 4 eq.) was 
then added over a period of 20 min and the resulting reaction 
mixture allowed to warm to room temperature.  After stirring for 
18 h at room temperature, the reaction was quenched by the 
addition of water (50 mL) and the aqueous solution extracted with 
DCM (4 x 50 mL).  The combined organic extracts were washed 
with brine (50 mL), dried (MgSO4), and the solvent removed at 
reduced pressure to afford the crude product.  Purification by basic 
silica gel column chromatography (Hexane/EtOAc, 80:20) 
afforded the desired product 22 as a yellow oily solid (3.49 g, 
8.64 mmol, 64%).  Crystals suitable for X-ray analysis were 
obtained by slow evaporation from methanol. Mp 130-133 °C; IR 
(KBr) νmax 3375, 3029, 2931, 1615, 1558, 1494, 1454, 1408, 1326, 
1214 102 cm-1; HRMS (ES+) m/z calcd for C27H26N2ONa 
419.1943, found 417.1939; 1H NMR δH (300 MHz, CDCl3) 7.68-
7.62 (d,  J = 7.5 Hz, 1H), 7.42-7.16 (m, 9H), 7.11-6.98 (m, 2H), 
6.93 (dd, J = 8.0, 1.0 Hz, 1H), 5.79 (d, J = 16.5 Hz, 1H), 5.25-5.09 
(m, 1H), 4.86 (d, J = 16.5 Hz, 1H), 4.76-4.58 (m, 2H), 4.52-4.35 
(m, 1H), 3.15 (d, J = 5.0 Hz, 1H), 2.40 (d, J = 7.0 Hz, 2H), 1.94, 
1.38 (dd, J = 6.5 Hz, 1.5 Hz, 3H); 13C NMR δC (100 MHz, CDCl3) 
173.6, 153.2, 140.6, 136.2, 135.9, 129.8, 129.0, 128.9, 128.4, 
127.6, 127.3, 126.7, 125.7, 124.5, 124.2, 124.0, 123.1, 116.9, 
116.0, 61.4, 54.9, 51.1, 44.0, 33.9, 17.8. 
 
(±)-10b-allyl-5-methyl-5,11-dihydro-10bH-indolo[2,5-
b]quinoline-11-carboxylic acid methyl ester (12) 
 
A solution of 13 (470 mg, 1.54 mmol) in acetone (20 mL) was 
added to a stirred mixture of CrO3 (772 mg, 7.72 mmol) and celite 
(2.00 g) in 1.5 M H2SO4 (10 mL).  After 5 hours, i-PrOH (2.0 mL, 
26 mmol) was added and stirring was continued for 0.5 hours.  The 
reaction mixture was filtered through celite and the celite was 
washed with EtOAc (50 mL).  Brine (50 mL) was added to the 
filtrate followed by sufficient NaHCO3(aq) to neutralise (pH 7) the 
aqueous phase.  The EtOAc was separated and the aqueous phase 
was further extracted with EtOAc (4 x 50 mL).  The combined 
extracts were dried (MgSO4) and the solvent was evaporated at 
reduced pressure to afford crude 23. The crude material was 
dissolved in MeOH (20 mL) and Me3SiCHN2 (1.54 mL of a 2.0 M 
solution in Et2O, 3.08 mmol) was added.  After stirring for 0.5 
hours, AcOH (0.5 mL) was added and stirring was continued for 
an additional 0.5 hours.  The solvent was evaporated at reduced 
pressure and the residue was partitioned between NaHCO3(aq) (10 
mL) and CH2Cl2 (10 mL).  The CH2Cl2 was separated and the 
aqueous phase was further extracted with CH2Cl2 (3 x 10 mL).  The 
combined extracts were dried (MgSO4) and the solvent was 
evaporated at reduced pressure.  The residue was purified by flash 
chromatography (5% EtOAc/hexane) to afford the title compound 
12 as a colourless crystalline solid (267 mg, 0.80 mmol, 52%).  Mp 
137-138 oC; IR (KBr) νmax: 2951, 1740, 1618, 1560, 1495, 1470, 
1400, 1215, 1161, 921, 751 cm-1; HRMS (ESI) m/z calcd for 
C21H21N2O2 333.1603, found 333.1599; 
1H NMR (300 MHz, 
CDCl3)  7.38-7.24 (m, 3H), 7.12-6.99 (m, 4H), 4.97-5.11 (m, 1H), 
4.66-4.76 (m, 2H), 4.09 (s, 1H), 3.94 (s, 3H), 3.61 (s, 3H), 2.87 
(dd, J = 14.0, 6.5 Hz, 1H), 2.55 (dd, J = 14.0, 8.0 Hz, 1H); 13C 
NMR (75 MHz, CDCl3)  172.6, 172.0, 156.0, 141.0, 136.4, 132.4, 
129.2, 129.0, 127.5, 123.0, 122.7, 122.4, 121.2, 118.4, 117.6, 
114.8, 53.3, 52.2, 49.2, 34.7, 33.0. 
 
(±)-10b,11-diallyl-5-methyl-5,11-dihydro-10bH-indolo[2,5-
b]quinoline-11-carboxylic acid methyl ester (10) 
 
LiHMDS (0.36 mL of a 1.0 M solution in THF, 0.36 mmol) was 
added to a solution of 12 (60 mg, 0.181 mmol) in THF (2 mL) at -
78 °C, maintained under an argon atmosphere.  The reaction 
mixture was warmed to 0 °C and then, after 1 hour, cooled to -78 
°C.  Allyl bromide (0.047 mL, 0.543 mmol) was added and the 
reaction mixture was slowly warmed to room temperature.  After 
16 hours, NH4Cl(aq) (0.3 mL) was added and the THF was 
evaporated at reduced pressure.  The residue was partitioned 
between water (1 mL) and CH2Cl2 (2 mL), the CH2Cl2 was 
separated and the aqueous phase was further extracted with 
CH2Cl2 (3 x 2 mL).  The combined CH2Cl2 extracts were dried 
(MgSO4) and the CH2Cl2 was evaporated at reduced pressure.  The 
crude product was purified by flash chromatography (5% to 15% 
EtOAc/hexane) followed by crystallisation from EtOAc/hexane to 
afford the title compound 10 as a colourless crystalline solid (39 
mg, 0.105 mmol, 59%).  Crystals form EtOAc/hexane were 
suitable for X-ray analysis.  Mp 171-173 oC; IR (KBr) νmax: 2984, 
2955, 1728, 1617, 1562, 1495, 1468, 1455, 1400, 1316, 1292, 
1233, 1220, 935, 759 cm-1; HRMS (ESI) m/z calcd for C24H25N2O2 
373.1916, found 373.1907; 1H NMR (300 MHz, CDCl3)  7.24-
7.23 (m, 3H), 7.06-6.97 (m, 5H), 5.47-5.32 (m, 1H), 5.07-4.93 (m, 
1H), 4.84-4.57 (m, 4H), 3.96 (s, 3H), 3.61 (s, 3H), 2.76 (dd, J = 
13.5, 8.0 Hz, 1H), 2.63 (dd, J = 14.0, 7.0 Hz, 1H), 2.39 (dd, J = 
13.5, 6.0 Hz, 1H), 2.03 (dd, J = 14.0, 7.0 Hz, 1H); 13C NMR (75 
MHz, CDCl3)  172.7, 171.7, 156.3, 140.0, 134.7, 133.3, 132.3, 
131.3, 129.0, 128.7, 123.7, 122.9, 122.6, 121.9, 119.0, 118.5,, 
117.5, 114.5, 58.3, 57.1, 52.2, 38.5, 38.1, 33.0. 
 
(±)-10b-allyl-11-hydroxymethyl-5-methyl-5,11-dihydro-10bH-
indolo[2,5-b]quinoline-11-carboxylic acid methyl ester (11) 
 
n-BuLi (0.27 mL of a 1.46 M solution, 0.394 mmol) was added to 
a mixture of i-Pr2NH (0.058 mL, 0.412 mmol) and THF (1 mL) at 
-78 °C, maintained under an argon atmosphere.  The reaction 
mixture was allowed to warm to room temperature and then, after 
0.5 hours, was cooled to -78 °C before a solution of 12 (65 mg, 
0.196 mmol) in THF (2 mL) was added.  The reaction mixture was 
warmed to -10 °C and after 1 hour formaldehyde, generated by 
heating paraformaldehyde (59 mg) to 150 °C, was bubbled through 
the vigorously stirred reaction mixture.  The reaction mixture was 
then allowed to warm to room temperature and was stirred for 1 
hour. NH4Cl(aq) (0.5 mL) was added and the THF was evaporated 
at reduced pressure.  The aqueous residue was extracted with 
CH2Cl2 (3 x 4 mL) and the combined CH2Cl2 extracts were dried 
(MgSO4).  The CH2Cl2 was evaporated at reduced pressure and the 
residue was purified by flash chromatography (20% to 40% 
EtOAc/hexane) to afford the title compound 11 as colourless 
crystals (55 mg, 0.152 mmol, 76%).  Crystals suitable for X-ray 
analysis were obtained from EtOAc/hexane. Mp 202-203 oC; IR 
(KBr) νmax: 3240, 2954, 1733, 1618, 1561, 1497, 1470, 1455, 1406, 
1311, 1235, 1162, 1116, 1066, 923,  805, 760, 731, 643 cm-1; 
HRMS (ESI) m/z calcd for C22H22N2O3Na 385.1528, found 
385.1527; 1H NMR (300 MHz, CDCl3)  7.36 (ddd, J = 8.5, 7.0, 
1.5 Hz, 1H), 7.25-7.28 (m, 2H), 6.97-7.15 (m, 5H), 4.92-5.07 (m, 
1H), 4.67-4.79 (m, 2H), 4.01 (s, 3H), 3.91 (dd, J = 11.5, 6.5 Hz, 
1H), 3.59 (s, 3H), 3.38 (dd, J = 11.5, 8.0 Hz, 1H), 2.77 (dd, J = 
13.5, 8.0 Hz, 1H), 2.51 (dd, J = 13.5, 6.5 Hz, 1H), 1.75 (dd, J = 
6.5, 8.0 Hz); 13C NMR (75 MHz, CDCl3)  172.8, 171.5  155.9, 
140.4, 134.3, 131.7, 131.0, 129.2, 129.2, 122.8, 122.7, 122.53, 
122.50, 118.9, 117.7, 114.8, 64.3, 58.8, 55.8, 52.6, 38.7, 33.0. 
 
(±)-10b-crotyl-5-benzyl-5,11-dihydro-10bH-indolo[2,5-
b]quinoline-11-carboxylic acid methyl ester (25) 
 
To a stirring mixture of CrO3 (630 mg, 6.3 mmol, 5 eq.) and celite 
(2 g) in 1.5M H2SO4 (10 mL) was added in one portion a solution 
of 22 (500 mg, 1.18 mmol, 1 eq.) in acetone (20 mL).   After 
stirring for 5 h at room temperature, i-PrOH (10 mL) was added 
and the reaction stirred for further 30 min.  The mixture was then 
filtered through celite and the celite washed with additional EtOAc 
(10 mL).  After adding brine (10 mL) to the filtrate, and the pH of 
the aqueous layer adjusted to pH 7 by addition of saturated 
aqueous NaHCO3 solution.  The organic phase was separated and 
the aqueous phase further extracted with EtOAc (4 x 10 mL).  The 
combined organic extracts were dried (MgSO4) and the solvent 
removed at reduced pressure to afford the crude acid 24.  The acid 
was then dissolved in MeOH (20 mL) and Me3SiCHN2 (1.25 mL 
of a 2.0M solution in Et2O, 2.36 mmol) was added.  After stirring 
for 30 min at room temperature, AcOH (0.5 mL) was added and 
the reaction mixture stirred for a further 30 min.  After this time 
the solvent was removed at reduced pressure and the residue 
partitioned between layers of saturated aqueous NaHCO3 solution 
(10 mL) and DCM (10 mL).  The organic phase was separated and 
the aqueous phase further extracted with DCM (3 x 10 mL).  The 
combined extracts were dried (MgSO4) and the solvent removed 
at reduced pressure.  The crude product was purified by flash 
column chromatography (Hexane/EtOAc, 95:5 to 90:10) to afford 
the desired product 25 as a colourless crystalline solid (124 mg, 
0.29 mmol, 25% over two steps).   
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Mp 145-147 °C; IR (KBr) νmax 3453, 3026, 2953, 2850, 1735, 
1558, 1493 cm-1; HRMS (ES+) m/z calcd for C28H27N2O2 
423.2073, found  423.2071; 1H NMR δH (400 MHz, CDCl3) 7.41-
7.14 (m, 8H, ArH), 7.11-7.09 (m, 1H), 7.06-6.93 (m, 4H), 5.76 (d, 
J = 16.5 Hz, 1H), 5.27-5.14 (m, 1H), 4.94 (d, J = 16.5 Hz, 1H), 
4.73-4.60 (m, 1H), 4.14 (s, 1H), 3.94 (s, 3H), 2.91 (dd, J = 14.0 
Hz, 6.0 Hz, 1H), 2.62 (dd, J = 14.5, 8.0 Hz, 1H), 1.37 (dd, 
J = 6.5, 0.5 Hz, 3H); 13C NMR δC (100 MHz, CDCl3) 172.9, 171.9, 
155.9, 140.7, 137.0, 136.8, 129.1, 128.9, 128.8 (2C), 127.4, 127.3, 
126.9, 124.5, 123.1, 122.7, 122.3, 121.5, 117.7, 115.8, 53.6, 52.1, 
50.2, 49.4, 33.4, 17.9.  
 
(±)-5-benzy-10b-(2-hydroxyethyl)-5H-indolo[2,3-b]quinolin-
11(10bH)-one (27) 
 
To a solution of 20 (1.00 g, 2.74 mmol) in THF : H2O (9:1, 20 mL) 
was added osmium tetroxide (2.5M solution in tBuOH, 0.2 mL, 
cat.) and NMO (0.97 g, 5.29 mmol, 2 eq.) and the mixture stirred 
at room temperature for 18 h. Na2SO3 (aq.) (20 mL) was added and 
the resulting mixture stirred for 30 min. Brine (20 mL) was added 
and the mixture extracted with DCM (3 × 50 mL) before the 
combined organic layer was dried (MgSO4), filtered and 
concentrated to afford the crude diol as a mixture of 
diastereoisomers. The crude product was purified by column 
chromatography (0-5 % MeOH / DCM) to give the diol as a yellow 
solid. To a solution of the diol in DCM (20 mL) was added 
iodosobenzene diacetate (1.06 g, 3.29 mmol) and the mixture 
stirred at room temperature for 2 hours. Sodium 
triacetoxyborohydride (1.16 g, 5.49 mmol) was then added and the 
mixture stirred for a further 2 hours. NaHCO3 (aq.) (20 mL) was 
added and the mixture extracted with DCM (3 x 20 mL).  The 
combined organic extracts were dried (MgSO4), filtered and the 
solvent removed at reduced pressure to give the crude product. 
Purification by column chromatography (20-30% EtOAc / 
Hexane) gave 27 as a yellow solid (890 mg, 88%, 2 steps).  Mp 
95-97 °C; IR (KBr) νmax 3200, 1695, 1468, 799, 755 cm-1; HRMS 
(ES+): m/z calcd for C24H21N2O2 369.1603, found: 369.1609. 
1H 
NMR δ (CDCl3, 400 MHz) 7.95 (dd, J = 7.5, 1.5 Hz, 1H), 7.76 
(dd, J = 7.5, 0.5 Hz, 1H), 7.51-6.92 (m, 11H), 5.85 (d, J = 16.5 Hz, 
1H), 5.15 (d, J = 16.5 Hz, 1H), 2.54-2.40 (m, 2H), 2.21-2.07 (m, 
2H). 13C NMR (126 MHz, CDCl3) δ 193.3, 172.6, 153.2, 144.2, 
135.9, 135.7, 132.5, 129.2, 129.0, 128.6, 127.6, 126.6 (2C), 124.7, 
123.6, 123.0, 119.1, 118.7, 115.7, 64.7, 60.4, 50.0, 43.2.  
 
(±)-5-benzyl-10b-(2-(benzyloxy)ethyl)-5,10b-
dihydrospiro[indolo[2,3-b]quinoline-11,2'-oxirane] (28) 
 
To a solution of 27 (50 mg, 0.136 mmol) and benzyl TCA (41 mg, 
0.163 mmol) in DCM (3 mL) was added TMS-OTf (30 mg, 0.136 
mmol) at 0 °C. After stirring for 30 minutes, the ice bath was 
removed and the reaction stirred for a further 18 hours at room 
temperature before NaHCO3 (aq.) (3 mL) was added. The mixture 
was extracted with DCM (3 x 3 mL) before the combined organic 
extracts were dried (MgSO4) filtered and concentrated to give the 
crude product. The crude was purified by column chromatography 
(10–20 % EtOAc / Hexane) to give a yellow oil. 
    To the yellow oil (122 mg, 0.266 mmol) in THF (4 mL) at -78 
°C was added chloroiodomethane (29 µL, 0.399 mmol) followed 
by methyl lithium – lithium bromide (1.5 M in THF, 266 µL, 0.399 
mmol). The mixture was stirred at -78 °C for 30 minutes before 
the cold bath was removed and the reaction stirred for a further 5 
hours at room temperature before NH4Cl (aq.) (10 mL) was added. 
The mixture was extracted with DCM (3 x 10 mL) before the 
combined organic extracts were dried (MgSO4) filtered and 
concentrated to give the crude product. The crude was purified by 
column chromatography (10–20 % EtOAc / Hexane) to give 28 as 
a yellow oil (83 mg, 51% - 2 steps).  
IR (KBr) νmax: 1719, 1555, 1492, 1467, 1451, 1208, 750, 695 cm-
1; HRMS (ES+): m/z calcd for C32H29N2O2 473.2224, found 
473.2217 [M+H]+; 1H NMR (400 MHz, CDCl3) δ 7.31 – 7.04 (m, 
16H), 6.93 (td, J = 7.5, 1.0 Hz, 1H), 6.81 (dd, J = 8.0, 0.5 Hz, 1H), 
5.66 (d, J = 16.5 Hz, 1H), 4.89 (d, J = 16.5 Hz, 1H), 4.10 (s, 2H), 
3.15 – 3.02 (m, 2H), 2.97 (d, J = 5.5 Hz, 1H), 2.46 (d, J = 5.5 Hz, 
1H), 2.42 – 2.27 (m, 2H); 13C NMR (101 MHz, CDCl3) δ 172.8, 
155.6, 141.1, 138.1, 136.8, 134.0, 129.4, 129.0 (2C), 128.8 (2C), 
128.3, 127.6 (2C), 127.5, 127.2, 126.4 (2C), 123.7, 123.2, 123.1, 
122.9, 122.8, 118.2, 115.1, 73.1, 66.5, 60.5, 53.7, 53.3, 49.6, 33.6. 
 
(±)-5-benzyl-10b-(2-((tert-butyldiphenylsilyl)oxy)ethyl)-5,10b-
dihydrospiro[indolo[2,3-b]quinoline-11,2'-oxirane] (30) 
 
To a solution of 27 (4.60 g, 12.5 mmol) in DCM (140 mL) at room 
temperature was added tert-butyl diphenyl silyl chloride (4.12 g, 
15.0 mmol) and imidazole (1.88 g, 27.6 mmol). The mixture was 
stirred at room temperature for 60 minutes before NH4Cl (aq.) (100 
mL) was added and the mixture extracted with DCM (3 x 100 mL). 
The combined organic layer dried (MgSO4), filtered and 
concentrated to give the crude product. Purification by column 
chromatography (5–15 % EtOAc / Hexane) to give a yellow solid. 
      The yellow solid (380 mg, 0.626 mmol) was taken up in THF 
(10 mL) at -78 °C was added chloroiodomethane (69 µL, 0.939 
mmol) followed by the dropwise addition of methyl lithium – 
lithium bromide (1.5 M in THF, 626 µL, 0.939 mmol). The 
mixture was stirred at -78 °C for 15 minutes before the cold bath 
was removed and the reaction stirred for a further 5 hours at room 
temperature. NH4Cl (aq.) (30 mL) was added and the mixture 
extracted with DCM (3 x 30 mL) before the combined organic 
extracts were dried (MgSO4) filtered and concentrated to give the 
crude product. The crude was purified by column chromatography 
(10–20 % EtOAc / Hexane) to give 30 as a yellow solid (330 mg, 
71% - 2 steps). Mp 46-49 °C; IR (KBr) νmax: 3069, 3044, 2926, 
2852, 1807, 1558, 1452, 1108, 700 cm-1; HRMS (ES+) m/z calcd 
for C41H40N2O2NaSi 643.2757, found 643.2762 [M+Na]
+; 1H 
NMR (300 MHz, CDCl3) δ 7.53 – 7.08 (m, 19H), 7.08 – 6.93 (m, 
2H), 6.93 – 6.75 (m, 2H), 5.53 (d, J = 16.5 Hz, 1H), 5.03 (d, J = 
16.5 Hz, 1H), 3.50 – 3.38 (ddd, J = 10.0, 9.0, 5.5 Hz, 1H), 3.26 
(ddd, J = 10.0, 9.0, 5.5 Hz, 1H), 2.93 (d, J = 5.5 Hz, 1H), 2.43 (d, 
J = 5.5 Hz, 1H), 2.25 (tdd, J = 13.5, 9.0, 6.0 Hz, 2H), 0.83 (s, 9H); 
13C NMR (101 MHz, CDCl3) δ 172.6, 155.3, 140.8, 136.6, 135.4 
(4C), 133.9, 133.5, 133.4, 129.5, 129.4, 129.3, 128.8 (3C), 127.6 
(2C), 127.5 (2C), 127.2, 126.5 (2C), 123.7, 123.2, 122.9, 122.7, 
118.1, 115.1, 60.4, 60.1, 53.5, 53.1), 49.4, 36.3, 26.8, 19.0.  
 
(±)-(-5-benzyl-10b-(2-((tert-butyldiphenylsilyl)oxy)ethyl)-10b,11-
dihydro-5H-indolo[2,3-b]quinolin-11-yl)methanol (31) 
 
 
To a solution of 30 (135 mg, 0.218 mmol) in THF (4 mL) at -78 
°C was added boron trifluoride diethyl etherate (135 µL, 1.090 
mmol) followed by sodium cyanoborohydride (34 mg, 0.545 
mmol). The mixture was slowly allowed to warm to room 
temperature over a period of 4 hours before stirring for a further 
12 hours at room temperature. NH4Cl (aq.) (10 mL) was added 
before the mixture being extracted with DCM (3 x 10 mL) and the 
combined organic layer dried (MgSO4), filtered and concentrated 
to give the crude product. Purification by column chromatography 
(20–40 % EtOAc / Hexane) gave 31 as a white solid (74 mg, 55%). 
Mp 112-115 °C; I.R. (KBr) νmax: 3212, 2926, 2251, 1644, 1555, 
1496, 1191, 1103, 700 cm-1; HRMS (ES+): m/z calcd for 
C41H43N2O2Si 623.3088, found 623.0383 [M+H]
+; 1H NMR (300 
MHz, CDCl3) δ 7.54 (d, J = 7.5 Hz, 1H), 7.39 – 7.00 (m, 19H), 
6.94 (t, J = 7.5 Hz, 1H), 6.87 – 6.77 (m, 2H), 5.28 (d, J = 16.5 Hz, 
1H), 4.96 (d, J = 16.5 Hz, 1H), 4.53 – 4.39 (m, 1H), 4.31 – 4.17 
(m, 1H), 3.30 – 3.12 (m, 1H), 3.01 – 2.81 (m, 2H), 2.01 (ddd, J = 
13.5, 9.0, 5.0 Hz, 1H), 1.80 (ddd, J = 13.5, 9.0, 5.0 Hz, 1H), 0.80 
(s, 9H); 13C NMR (101 MHz, CDCl3) δ 174.1, 156.0, 140.6, 136.9, 
136.5, 135.4, 135.3 (2C), 133.6, 133.5, 129.5, 128.7 (2C), 127.9, 
127.5 (2C), 127.1 (2C), 126.7 (2C), 125.4, 123.5, 123.3, 122.3, 
117.7, 115.6, 61.7, 60.2, 52.3, 49.6, 44.9, 33.0, 26.8, 19.0.  
 
 (±)-5-benzyl-10b-(2-((tert-butyldiphenylsilyl)oxy)ethyl)-11-
hydroxy-10b,11-dihydro-5H-indolo[2,3-b]quinoline-11-
carbaldehyde (33) 
 
To a solution of 31 (75 mg, 0.120 mmol) in CDCl3 (3 mL) was 
added Dess-Martin periodinane (61 mg, 0.144 mmol) and the 
mixture was stirred at room temperature for 48 hours. Na2S2O3 (aq.) 
(3 mL) and NaHCO3 (aq.) (3 mL) were added and the mixture stirred 
for a further 30 minutes before the mixture was extracted with 
DCM (3 x 5 mL). The combined organic layers were dried 
(MgSO4), filtered and concentrated to give the crude product 32. 
Purification by column chromatography (10–25 % EtOAc / 
Hexane) gave 33 as a white solid (50 mg, 65%). M.p. 101-103 °C; 
I.R. (KBr) νmax: 3435, 3063, 2928, 2855, 1725, 1556, 1467, 1453, 
1207, 1110, 821, 737, 701, 503 cm-1; HRMS (ES-): m/z calcd for 
C41H39N2O3Si 635.2730, found 635.2722  [M-H]
-; 1H NMR (400 
MHz, CDCl3) δ 9.08 (d, J = 1.0 Hz, 1H), 7.50 (m, 2H), 7.44 – 7.22 
(m, 18H), 7.07 (t, J = 7.5 Hz, 1H), 7.01 – 6.95 (m, 2H), 5.53 (d, J 
= 16.5 Hz, 1H), 5.25 (s, 1H), 5.20 (d, J = 16.5 Hz, 1H), 3.43 (t, J 
= 7.0 Hz, 2H), 2.43 (dt, J = 14.0, 7.0 Hz, 1H), 1.97 (dt, J = 14.0, 
6.0 Hz, 1H), 0.98 (s, 9H); 13C NMR (101 MHz, CDCl3) δ 196.7, 
172.6, 155.6, 140.0, 136.6, 135.5 (2C), 135.4 (2C), 134.0, 132.9, 
132.7, 130.2, 129.7, 129.7, 129.2, 128.8 (2C), 127.7 (2C), 127.6 
(2C), 127.4, 127.0, 126.9 (2C), 123.7, 123.4, 123.1, 122.3, 118.3, 
115.5, 81.6, 60.0, 55.4, 49.3, 34.6, 26.8, 19.1.  
 
11-allyl-5-methyl-5H-indolo[2,3-b]quinoline (35) 
 
t-BuOK (0.83 mL of a 1.0 M solution in t-BuOH, 0.830 mmol) 
was added to a stirred mixture of 5,10b-dihydro-10b-allyl-5-
methyl-10bH-indolo[2,3-b]quinolin-11-one (14) (100 mg, 0.347 
mmol), TosMIC (88 mg, 0.451 mmol) and DME (2.5 mL) that was 
cooled to 0 °C and maintained under an argon atmosphere.  After 
0.5 hours, the reaction mixture was allowed to warm to room 
temperature and the stirring was continued for 1 hour.  Water (2 
mL) was added and the mixture was extracted with CH2Cl2 (3 x 5 
mL).  The combined extracts were washed with brine (10 mL) and 
then dried (MgSO4).  The solvent was evaporated at reduced 
pressure and the residue was purified by flash chromatography 
(50% to 80% EtOAc/hexane) to afford the title compound 35 as an 
orange solid (57 mg, 0.209 mmol, 61%).  Mp 125-127 oC; IR 
(KBr) νmax: 3049, 1627, 1608, 1565, 1525 cm-1; HRMS (EI) m/z 
calcd for C19H16N2O 272.1313, found 272.1317; 
1H NMR (500 
MHz, CDCl3)  8.17 (d, J = 8.0 Hz, 1H), 8.08 (d, J = 7.5 Hz, 1H), 
7.78-7.73 (m, 3H), 7.54 (t, J = 7.5 Hz, 1H), 7.49-7.45 (m, 1H), 
7.24 (t, J = 7.5 Hz, 1H), 6.19 (ddt, J = 16.5, 10.5, 5.5 Hz, 1H), 
5.18-5.13 (m, 2H), 4.35-4.31 (m, 5H); 13C NMR (101 MHz, 
CDCl3)  155.8, 155.3, 141.0, 137.1, 133.3, 130.4, 128.9, 126.0, 
124.3, 123.3, 122.0, 120.8, 120.0, 117.82, 117.79, 114.7, 33.3, 
33.0.   
 
(±)-10b-(2',2'-dimethyl[1,3]dioxolan-4'-ylmethyl)-5-methyl-
5,10b-dihydroindolo[2,3-b]quinolin-11-one (36) and (±)-10b-
(2',2'-dimethyl[1,3]dioxolan-4'-ylmethyl)-5-methyl-5,10b-
dihydroindolo[2,3-b]quinolin-11-one (36*) 
 
Osmium tetroxide (3.26 mL of a 2.5% solution in t-BuOH) was 
added to a vigorously stirred solution of 5,10b-dihydro-10b-allyl-
5-methyl-10bH-indolo[2,3-b]quinolin-11-one (130) (1.50 g, 5.20 
mmol) and NMO (1.28 g, 10.9 mmol) in THF/water (9:1, 40 mL).  
After 24 hours a saturated solution of sodium sulphite (90 mL) was 
added and stirring was continued for 0.5 hours before the reaction 
mixture was extracted with CH2Cl2 (3 x 150 mL).  The combined 
CH2Cl2 extracts were washed with brine (200 mL), dried (MgSO4) 
and the solvent was evaporated at reduced pressure.  The residue 
was triturated with Et2O and the yellow solids were collected by 
filtration.  
    2,2-dimethoxypropane (9.57 mL, 78.0 mmol) and PPTS (1.31 
g, 5.21 mmol) were added to a stirred suspension of the crude solid 
in CH2Cl2 (100 mL), maintained under an argon atmosphere.  After 
2 days, when all the solids had gone into solution, NaHCO3(aq) (50 
mL) was added and the CH2Cl2 was separated.  The aqueous phase 
was further extracted with CH2Cl2 (3 x 25 mL).  The combined 
extracts were dried (MgSO4) and the solvent was evaporated at 
reduced pressure.  The residue was purified by flash 
chromatography (5% to 10% EtOAc/hexane) to yield the title 
compounds 36/36* as a 1:1 mixture of diastereomers (1.32 g, 3.64 
mmol, 70%).  Whilst complete separation of the diastereomers 
could not be achieved, small highly enriched samples of each 
diastereomer could be obtained (122 mg of the less polar isomer 
and 50 mg of the more polar) by careful flash chromatography.  
Less polar isomer: IR (film) νmax: 2986, 2937, 1694, 1563 cm-1; 
HRMS (CI) m/z calcd for C22H23N2O3 363.1709, found 363.1698; 
1H NMR (400 MHz, CDCl3)  7.92 (dd, J = 7.5, 1.5 Hz, 1H), 7.70 
(d, J = 7.0 Hz 1H), 7.58 (t, J = 8.0 Hz, 1H), 7.43 (d, J = 7.5 Hz, 
1H), 7.36 (td, J = 7.5, 1.5 Hz, 1H), 7.18-7.06 (m, 3H), 3.69 (s, 3H), 
3.58-3.51 (m, 1H), 3.27 (dd, J = 8.5, 6.0 Hz, 1H), 3.01 (dd, J = 8.5, 
6.0 Hz, 1H), 2.45 (dd, J = 13.5, 5.5 Hz, 1H), 2.18 (dd, J = 13.5, 7.0 
Hz, 1H), 1.22 (s, 3H), 1.17 (s, 3H); 13C NMR (101 MHz, CDCl3) 
 193.2, 172.3, 153.9, 145.4, 136.1, 132.4, 129.3, 128.6, 124.7, 
123.4, 122.3, 118.8, 118.4, 114.5, 108.4, 72.0, 69.3, 64.4, 44.6, 
33.3, 26.8, 25.6.   
More polar isomer: IR (film) νmax: 2986, 2937, 1696, HRMS (CI) 
m/z calcd for C22H23N2O3 363.1709, found 363.1700; 
1H NMR 
(300 MHz, CDCl3)  7.94 (dd, J = 8.5, 1.5 Hz, 1H), 7.77 (d, J = 
7.5 Hz, 1H), 7.61 (td, J = 8.0, 1.5 Hz, 1H), 7.44-7.34 (m, 2H), 7.21-
7.11 (m, 3H), 3.91-3.82 (m, 2H), 3.71 (s, 3H), 3.33-3.26 (m, 1H), 
2.51 (dd, J = 13.5, 6.0 Hz, 1H), 1.88 (dd, J = 13.5, 6.0 Hz, 1H), 
1.89 (s, 3H), 1.15 (s, 3H); 13C NMR (101 MHz, CDCl3)  193.1, 
173.0, 153.7, 145.0, 135.8, 133.0, 129.2, 128.9, 125.0, 123.5, 
122.7, 119.5, 118.9, 114.6, 109.0, 72.1, 69.3, 64.6, 45.6, 33.3, 
26.8, 25.4.   
 
Preparation of (±)-11-allyl-10b-(2,2-dimethyl[1,3]dioxolan-4-
ylmethyl)-5-methyl-5,11-dihydro-10bH-indolo[2,3-b]quinolin-
11-carbonitrile (38) via (±)-10b-((2,2-dimethyl-1,3-dioxolan-4-
yl)methyl)-5-methyl-10b,11-dihydro-5H-indolo[2,3-b]quinoline-
11-carbonitrile (37) and epi (±)-10b-((2,2-dimethyl-1,3-dioxolan-
4-yl)methyl)-5-methyl-10b,11-dihydro-5H-indolo[2,3-
b]quinoline-11-carbonitrile (37*) 
 
t-BuOK (0.73 mL of a 1.0 M solution in t-BuOH, 0.730 mmol) 
was added to a stirred mixture of enriched 36 (110 mg, 0.304 
mmol), TosMIC (77 mg, 0.396 mmol) and DME (2.5 mL), cooled 
to 0 °C and maintained under an argon atmosphere.  After 0.5 
hours, the reaction mixture was allowed to warm to room 
temperature and the stirring was continued for 0.5 hour.  Water (2 
mL) was added and the mixture was extracted with CH2Cl2 (3 x 5 
mL).  The combined extracts were washed with brine (10 mL) and 
then dried (MgSO4).  The solvent was evaporated at reduced 
pressure and the residue was purified by flash chromatography 
(5% to 10% EtOAc/hexane) to afford a sample that was 
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predominantly 37 as a mixture of diastereomers (37* = minor 
isomer) that could not be separated (59 mg).  IR (KBr) νmax: 2985, 
2934, 2243, 1562 cm-1; HRMS (CI) m/z calcd for C23H24N3O2 
374.1869, found 374.1858; 1H NMR (400 MHz, CDCl3) δ 7.59 – 
7.54 (m, 2H-major and 2H-minor), 7.45 – 7.30 (m, 3H-major 
and 3H-minor), 7.28 – 7.25 (m, 1H-minor), 7.22 (d, J = 7.2 Hz, 
1H-minor), 7.16 – 7.04 (m, 3H-major and 1H-minor), 4.23 (s, 
1H-major), 4.16 (s, 1H-minor), 3.67 (s, 3H-minor), 3.59 (s, 3H-
major), 3.50 (q, J = 6.0 Hz, 1H-minor), 3.42 (q, J = 6.0 Hz, 1H-
major), 3.26 – 3.18 (m, 1H-major and 1H-minor), 3.07 – 3.02 
(m, 1H-major), 2.95 (dd, J = 8.5, 6.5 Hz, 1H-minor), 2.29 – 
2.21 (m, 1H-major and 1H minor), 2.12 – 2.05 (m, 1H-major), 
1.75 (dd, J = 13.5, 6.5 Hz, 1H-minor), 1.19 – 1.13 (m, 6H major 
and 6H minor). 
      This mixture of diastereomers (59 mg) was dissolved in THF 
(1 mL) and cooled to -78 °C, under an argon atmosphere.  
LiHMDS (0.24 mL of a 1.0 M solution in THF) was added and the 
reaction mixture was warmed to 0 °C for 0.5 hours.  The orange 
reaction mixture was then cooled to -78 °C and allyl bromide (27 
μL, 0.312 mmol) was added.  After stirring -78 °C for 2 hours, the 
reaction mixture slowly warmed to room temperature and stirred 
for a further 16 hours.  NH4Cl(aq) (0.5 mL) was added and the 
solvent was evaporated at reduced pressure.  The residue was 
partitioned between CH2Cl2 (1 mL) and water (1 mL).  The CH2Cl2 
was separated and the aqueous phase was further extracted with 
CH2Cl2 (3 x 1 mL).  The combined extracts were dried (MgSO4) 
and the solvent was evaporated at reduced pressure.  The residue 
was purified by chromatography (5% to 10% EtOAc/hexane) to 
afford 38 as a colourless oil (43 mg, 0.104 mmol, 34%).  IR (film) 
νmax: 2985, 2241, 1564; HRMS (EI) m/z calcd for C26H27N3O2 
413.2103, found 413.1998; 1H NMR (400 MHz, CDCl3)  7.50 (d, 
J = 7.5 Hz, 1H), 7.43-7.31 (m, 4H), 7.12-7.03 (m, 3H, 3 x ArH), 
5.49-5.38 (m, 1H,), 5.05-5.01 (m, 1H), 4.87-4.82 (m, 1H), 3.61 (s, 
3H), 3.43-4.39 (m, 1H), 3.26 (dd, J = 8.5, 6.0 Hz, 1H), 3.06 (dd, J 
= 8.5, 6.5 Hz, 1H), 2.39 (dd, J= 14.0, 6.5 Hz, 1H), 2.24-2.33 (m, 
2H), 2.18 (dd, J = 14.0, 7.0 Hz, 1H), 1.18 (s, 3H), 1.15 (s, 3H); 13C 
NMR (101 MHz, CDCl3)  170.9, 156.4, 138.8, 133.3, 130.7, 
130.20, 130.17, 129.3, 123.4, 123.0, 122.5, 121.0, 120.5, 119.6, 
118.2, 115.3, 108.5, 72.2, 69.6, 55.3, 49.5, 38.9, 38.6, 33.0, 26.9, 
25.7.   
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structures in this paper have been deposited with the Cambridge 
Crystallographic Data Centre as supplementary publication 
numbers CCDC 1582892 (10); CCDC 1582893 (22); CCDC 
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Additional results, discussion and discussion of supplementary 
compounds are discussed in the ESI. 
 
 
